Skip to main content

Table 2 The role of m6A-binding proteins in human solid cancers and hematological malignancy

From: m6A-binding proteins: the emerging crucial performers in epigenetics

Cancersm6A readersTarget RNAsMechanismReference
Hepatocellular carcinomaYTHDF1SnailAccelerating the translation of Snail mRNA[47]
YTHDF2EGFRDestabilizing EGFR mRNA[42]
YTHDF2IL-11, SERPINE2Increasing the degradation of IL-11 and SERPINE2 mRNAs[43]
YTHDF2SOCS2Facilitating SOCS2 mRNA decay[44]
IGF2BP1/2/3MYCEnhancing the expression of MYC mRNA[32]
IGF2BP1SRFPromoting SRF mRNA translation[48]
Colorectal cancerYTHDF1β-catenin, WNT6, FZD9Increasing the expression of β-catenin, WNT6 and FZD9A to activate Wnt/β-catenin pathway[49]
YTHDF3GAS5Enhancing the degradation of lncRNA GAS5[50]
YTHDC1circNSUN2Facilitating circNSUN2 export from nucleus to cytoplasm[51]
IGF2BP2HMGA2Forming a circNSUN2/IGF2BP2 complex to fortify the stability of HMGA2[51]
IGF2BP2SOX2Stabilizing SOX2 mRNA[52]
Gastric cancerIGF2BP1SEC62Augmenting SEC62 mRNA translation[53]
IGF2BP3HDGFFacilitating HDGF mRNA expression[54]
HuRZMYM1Fortifying the stability of ZMYM1 mRNA[116]
Lung cancerYTHDF1CDK2, CDK4, cyclinD1Promoting the translations of CDK2, CDK4 and cyclinD1[56]
YTHDF1Keap1Leading to cisplatin resistance of tumor cells via modulating the Keap1-Nrf2-AKR1C1 axis[56]
YTHDF1/3YAPUp-regulating YAP expression[57]
YTHDF26PGDFacilitating 6PGD degradation[55]
YTHDF3MALAT1Increasing MALAT1 stability[57]
MELLT3EGFR, TAZAccelerating the translation of EGFR and TAZ[58]
Bladder cancerYTHDF1/3ITGA6Promoting ITGA6 mRNA translation[59]
YTHDF1CDCP1Enhancing the expression of CDCP1 mRNA[60]
MELLT3CDCP1Facilitating CDCP1 translation and strengthening the binding of YTHDF1 to CDCP1[60]
Endometrial cancerYTHDF1PHLPP2Increasing the expression of PHLPP2[61]
YTHDF2PRR5, PRR5L, mTORDiminishing the abundance of PRR5, PRR5L, and mTOR[61]
Ovarian cancerYTHDF1EIF3CTargeting at EIF3C to enhance its translation efficiency[62]
Cervical cancerYTHDF2GAS5Abrogating the GAS5 expression[63]
MelanomaYTHDF2PD-1 (PDCD1), CXCR4, SOX10Downregulating the mRNA and protein levels of three key intrinsic pro-tumorigenic factors, including PD-1 (PDCD1), CXCR4 and SOX10[64]
YTHDF1HINT2Promoting the translation of HINT2 mRNA[65]
Breast cancerYTHDF2BNIP3Facilitating the degradation of BNIP3 mRNA[66]
Pancreatic cancerIGF2BP2DANCREnhancing the DANCR expression[67]
Acute myeloid leukemiaYTHDF2TNFR2Reducing the TNFR2 expression[81]
YTHDF2MYC, CEBPAAccelerating the decay of MYC and CEBPA[82]